South Dakota eyes $750,000 in annual savings from new Medicaid drug pricing plan
Gov. Larry Rhoden stands beside President Trump as they unveil the GENEROUS Model at the White House.
South Dakota eyes $750,000 in annual savings from new Medicaid drug pricing plan
Governor Rhoden joins Trump and HHS chief to launch the GENEROUS Model, tying drug prices to foreign rates.
Governor Larry Rhoden faced rising Medicaid prescription costs, stood in the Oval Office with President Donald Trump on September 19, 2026, and heard about a federal program that could shave $750,000 off South Dakota’s drug bill each year.
Medicaid officials have long worried about the growing share of state budgets that goes to brand‑name medicines. In recent months, the pressure has felt like a weight pressing on clinic floors across the Badlands. Patients watch their co‑pays inch upward while providers scramble for alternatives.
Enter the GENEROUS Model, a five‑year voluntary scheme that links Medicaid drug prices to those paid in selected foreign markets. States that sign on can demand extra rebates from manufacturers on drugs that meet the model’s criteria.
South Dakota has already pinpointed three medications that could qualify.
“The program could reduce prescription drug costs for South Dakota’s Medicaid program and taxpayers,” Rhoden said during the announcement. He added that the state will have flexibility to select drugs based on potential savings.
President Trump, flanked by Health and Human Services Secretary Robert F. Kennedy Jr. and CMS Administrator Dr. Mehmet Oz, framed the rollout as a win for “American families who struggle with high drug prices.” The Oval Office crowd included Arkansas Gov. Sarah Huckabee Sanders and Mississippi Gov. Tate Reeves, all nodding as the administration outlined the model’s mechanics.
Under the voluntary program, participating states can receive additional rebates from drug manufacturers on medications included in the model. South Dakota’s officials said the three identified drugs could together generate the projected $750,000 annual saving.
States must finalize participation agreements by Sept. 30, giving them a narrow window to decide whether to join the federal effort.
Why the GENEROUS Model matters for everyday South Dakotans
The model’s core idea is simple: if a drug costs less abroad, it should cost less here. By anchoring prices to international benchmarks, the federal government hopes to curb the steep price hikes that have left many families choosing between medicine and rent.
For a state like South Dakota, where Medicaid covers roughly 10 % of the population, even a modest cut translates into real dollars that can be redirected to other health services. The $750,000 figure may seem modest against a multi‑billion‑dollar budget, but it represents a tangible reduction in taxpayer burden.
Political backdrop
Friday’s announcement came as President Trump announced a ban on several news outlets, signaling a contentious media environment. At the same time, the administration was pushing other cost‑saving measures, such as the all‑famous “most‑favored‑nation” drug pricing program that now includes all 50 states, D.C., and Puerto Rico.
In a separate, more flamboyant moment, Trump urged Gov. Rhoden to consider adding his likeness to Mount Rushmore, a request that drew chuckles and eye‑rolls from onlookers.
How the rebate mechanism works
The GENEROUS Model requires manufacturers to disclose the prices they receive in the selected foreign markets. If a U.S. Medicaid price exceeds that benchmark, the state can negotiate a rebate equal to the difference, plus an additional percentage to encourage compliance. This approach mirrors earlier federal efforts that targeted high‑cost specialty drugs, but expands the scope to a broader set of medications.
South Dakota’s health officials have already begun data collection, comparing current Medicaid reimbursements with the foreign price lists provided by the Health‑Canada and European Medicines Agency databases. Early calculations suggest that the three target drugs, two cardiovascular agents and one insulin analog, are priced roughly 30 % higher in the United States than in Canada.
Potential impact on patients and providers
For patients, lower Medicaid drug prices could mean reduced co‑payments and fewer gaps in therapy. Rural clinics, which serve a large share of the state’s Medicaid population, often face inventory challenges when high‑cost drugs are unavailable or unaffordable. By lowering the cost ceiling, pharmacies may be able to keep a wider array of essential medicines in stock.
Providers have expressed cautious optimism. While they welcome any measure that eases the financial strain on their patients, some physicians worry about the administrative burden of tracking rebate eligibility. The state’s Medicaid agency has pledged to create a streamlined reporting portal to minimize paperwork for prescribers.
Budgetary considerations and next steps
South Dakota’s fiscal year runs from July 1 to June 30. The projected $750,000 saving represents less than 0.1 % of the state’s total Medicaid expenditure, but it frees up funds that could be redirected toward mental‑health services, which have seen rising demand in recent years. Lawmakers are already discussing earmarking a portion of the savings for expanding tele‑health coverage in underserved counties.
The deadline of Sept. 30, 2026 gives the state just over a month to finalize the participation agreement, conduct a public comment period, and align its Medicaid contracts with the new rebate structure. If the agreement is signed, the first set of rebates is expected to be processed in early 2027, with the savings reflected in the 2027‑2028 budget cycle.
Sources & Further Reading
What Happens Next
- Sept. 30, 2026 — Deadline for South Dakota to sign the GENEROUS Model participation agreement.
- Oct. 15, 2026 — CMS releases the first list of qualifying medications for participating states.
Comments